SIGA Technologies, Inc. (SIGA)
Chart Events
Performance Outlook
| Previous Close | 22.19 |
| Open | 22.20 |
| Bid | 23.65 x 1100 |
| Ask | 23.69 x 1100 |
| Day's Range | 21.92 - 24.42 |
| 52 Week Range | 5.84 - 24.42 |
| Volume | |
| Avg. Volume | 16,599,379 |
| Market Cap | 1.721B |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | 21.43 |
| EPS (TTM) | 1.10 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | May 16, 2022 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SIGA
Related Research
- SIGA Technologies Inc.Analyst Report: Emergent BioSolutions IncEmergent BioSolutions makes vaccines and other products intended to protect civilian and military populations from emerging infectious diseases and chemical, biological or nuclear attacks. The company generates its revenue from product sales of its smallpox vaccine (ACAM2000), its anthrax vaccines (BioThrax and AV7909), and its Narcan nasal spray (a treatment for opioid overdoses), as well as from contract development and manufacturing services and contracts and grants. The USG is the company's primary customer, and provides EBS with significant product development funding. EBS shares are a component of the S&P 400 Index. The company has approximately 2,400 employees.RatingFair ValueEconomic Moat22 days agoArgus Research
- GlobeNewswire
SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®
- IV TPOXX is an Important Option for Those Unable to Swallow – - Option to Fund Post-Marketing Field Study for IV TPOXX also Exercised – NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of procurement options under its 75A50118C00019 (19C) contract with the U.S. Department of Health and Human Services for the delivery to the U.S. government of intravenous (IV) formulation of TPOXX t
- Barrons.com
SIGA Will Seek FDA Approval of Monkeypox Treatment When Data Is Available, CEO Says
The monkeypox outbreak has sent the drugmaker's stock up more than 200% this year, though its antiviral remains hard to access in the U.S.
- Investor's Business Daily
How Siga Is Turning Its Biowarfare Soldier Onto This Outbreak ... And The Next
The medicine Siga Technologies developed to combat biowarfare is now being used in the ongoing viral outbreak, and Siga stock has exploded.
